Belite Bio to Participate in the BTIG Virtual Biotechnology Conference

Group 1 - Belite Bio, Inc is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs [2] - The company is participating in the BTIG Virtual Biotechnology Conference on July 29-30, 2025, allowing for one-on-one meetings with management [1] - Belite's lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye, currently evaluated in multiple clinical studies [2] Group 2 - The specific diseases targeted by Belite include Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD) [2] - Tinlarebant is being assessed in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) for STGD1, as well as a Phase 3 study (PHOENIX) for GA [2]